Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy
HERAKLES was a 1-year randomized, multicenter trial. Patients were randomized at 3 months after kidney transplantation to remain on cyclosporine-based therapy, switch to everolimus without a calcineurin inhibitor (CNI), or switch to everolimus with low-exposure cyclosporine. Overall, 417 of 497 (83....
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
02 May 2018
|
| In: |
American journal of transplantation
Year: 2018, Jahrgang: 18, Heft: 12, Pages: 2965-2976 |
| ISSN: | 1600-6143 |
| DOI: | 10.1111/ajt.14897 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1111/ajt.14897 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.14897 
|
| Verfasserangaben: | Claudia Sommerer, Michael Duerr, Oliver Witzke, Frank Lehner, Wolfgang Arns, Volker Kliem, Daniel Ackermann, Markus Guba, Johannes Jacobi, Ingeborg A. Hauser, Rolf Stahl, Petra Reinke, Thomas Rath, Justyna Veit, Arianeb Mehrabi, Martina Porstner, Klemens Budde on behalf of the HERAKLES Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693419777 | ||
| 003 | DE-627 | ||
| 005 | 20251014094852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200327s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.14897 |2 doi | |
| 035 | |a (DE-627)1693419777 | ||
| 035 | |a (DE-599)KXP1693419777 | ||
| 035 | |a (OCoLC)1341311508 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sommerer, Claudia |d 1971- |e VerfasserIn |0 (DE-588)121857654 |0 (DE-627)705680002 |0 (DE-576)292921829 |4 aut | |
| 245 | 1 | 0 | |a Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy |c Claudia Sommerer, Michael Duerr, Oliver Witzke, Frank Lehner, Wolfgang Arns, Volker Kliem, Daniel Ackermann, Markus Guba, Johannes Jacobi, Ingeborg A. Hauser, Rolf Stahl, Petra Reinke, Thomas Rath, Justyna Veit, Arianeb Mehrabi, Martina Porstner, Klemens Budde on behalf of the HERAKLES Study Group |
| 264 | 1 | |c 02 May 2018 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.03.2020 | ||
| 520 | |a HERAKLES was a 1-year randomized, multicenter trial. Patients were randomized at 3 months after kidney transplantation to remain on cyclosporine-based therapy, switch to everolimus without a calcineurin inhibitor (CNI), or switch to everolimus with low-exposure cyclosporine. Overall, 417 of 497 (83.9%) patients from the core study entered a 4-year extension study. The randomized regimen was continued to year 5 in 75.9%, 41.9% and 24.6% of patients in the standard-CNI, CNI-free and low-CNI groups, respectively. Adjusted estimated GFR at year 5 was significantly higher in the CNI-free group versus standard CNI (difference 7.2 mL/min/1.73 m2, P < .001) or low CNI (difference 7.6 mL/min/1.73 m2, P < .001). For patients who continued randomized therapy for 5 years, differences were 14.4 mL/min/1.73 m2 and 10.1 mL/min/1.73 m2, respectively. Biopsy-proven acute rejection occurred during the 4-year extension study in 7.6%, 8.6%, and 9.0% of patients in the standard-CNI, CNI-free and low-CNI groups, respectively (P = .927). In conclusion, conversion to a CNI-free everolimus regimen 3 months after kidney transplantation improved long-term graft function, particularly in patients who continued the CNI-free regimen. Low CNI with everolimus did not improve renal function. Efficacy was comparable between groups but frequent immunosuppression changes should be taken into account. | ||
| 650 | 4 | |a clinical research/practice | |
| 650 | 4 | |a immunosuppressant - calcineurin inhibitor: cyclosporine A (CsA) | |
| 650 | 4 | |a immunosuppressant - mechanistic target of rapamycin (mTOR) | |
| 650 | 4 | |a immunosuppressant - mechanistic target of rapamycin: everolimus | |
| 650 | 4 | |a immunosuppression/immune modulation | |
| 650 | 4 | |a kidney transplantation/nephrology | |
| 700 | 1 | |a Duerr, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Witzke, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lehner, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arns, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kliem, Volker |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ackermann, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guba, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jacobi, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hauser, Ingeborg A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stahl, Rolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reinke, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rath, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Veit, Justyna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mehrabi, Arianeb |d 1967- |e VerfasserIn |0 (DE-588)137664583 |0 (DE-627)594829763 |0 (DE-576)304831263 |4 aut | |
| 700 | 1 | |a Porstner, Martina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Budde, Klemens |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation |d [Amsterdam] : Elsevier, 2001 |g 18(2018), 12, Seite 2965-2976 |h Online-Ressource |w (DE-627)328318353 |w (DE-600)2045621-9 |w (DE-576)094404267 |x 1600-6143 |7 nnas |a Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:12 |g pages:2965-2976 |g extent:12 |a Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1111/ajt.14897 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.14897 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200327 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 137664583 |a Mehrabi, Arianeb |m 137664583:Mehrabi, Arianeb |d 910000 |d 910200 |e 910000PM137664583 |e 910200PM137664583 |k 0/910000/ |k 1/910000/910200/ |p 15 | ||
| 998 | |g 121857654 |a Sommerer, Claudia |m 121857654:Sommerer, Claudia |d 50000 |e 50000PS121857654 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1693419777 |e 3614729702 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"12 S."}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy","title":"Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy"}],"person":[{"display":"Sommerer, Claudia","family":"Sommerer","role":"aut","given":"Claudia"},{"display":"Duerr, Michael","family":"Duerr","role":"aut","given":"Michael"},{"family":"Witzke","given":"Oliver","role":"aut","display":"Witzke, Oliver"},{"display":"Lehner, Frank","given":"Frank","role":"aut","family":"Lehner"},{"family":"Arns","given":"Wolfgang","role":"aut","display":"Arns, Wolfgang"},{"family":"Kliem","role":"aut","given":"Volker","display":"Kliem, Volker"},{"family":"Ackermann","role":"aut","given":"Daniel","display":"Ackermann, Daniel"},{"family":"Guba","role":"aut","given":"Markus","display":"Guba, Markus"},{"display":"Jacobi, Johannes","family":"Jacobi","given":"Johannes","role":"aut"},{"display":"Hauser, Ingeborg A.","given":"Ingeborg A.","role":"aut","family":"Hauser"},{"family":"Stahl","given":"Rolf","role":"aut","display":"Stahl, Rolf"},{"role":"aut","given":"Petra","family":"Reinke","display":"Reinke, Petra"},{"display":"Rath, Thomas","given":"Thomas","role":"aut","family":"Rath"},{"role":"aut","given":"Justyna","family":"Veit","display":"Veit, Justyna"},{"display":"Mehrabi, Arianeb","role":"aut","given":"Arianeb","family":"Mehrabi"},{"display":"Porstner, Martina","family":"Porstner","given":"Martina","role":"aut"},{"role":"aut","given":"Klemens","family":"Budde","display":"Budde, Klemens"}],"recId":"1693419777","name":{"displayForm":["Claudia Sommerer, Michael Duerr, Oliver Witzke, Frank Lehner, Wolfgang Arns, Volker Kliem, Daniel Ackermann, Markus Guba, Johannes Jacobi, Ingeborg A. Hauser, Rolf Stahl, Petra Reinke, Thomas Rath, Justyna Veit, Arianeb Mehrabi, Martina Porstner, Klemens Budde on behalf of the HERAKLES Study Group"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"02 May 2018"}],"id":{"doi":["10.1111/ajt.14897"],"eki":["1693419777"]},"note":["Gesehen am 27.03.2020"],"relHost":[{"origin":[{"publisherPlace":"[Amsterdam] ; Copenhagen ; Oxford [u.a.] ; Oxford [u.a.]","dateIssuedDisp":"2001-","publisher":"Elsevier ; Munksgaard ; Blackwell ; Wiley-Blackwell","dateIssuedKey":"2001"}],"id":{"eki":["328318353"],"issn":["1600-6143"],"zdb":["2045621-9"],"doi":["10.1111/(ISSN)1600-6143"]},"part":{"volume":"18","pages":"2965-2976","text":"18(2018), 12, Seite 2965-2976","extent":"12","issue":"12","year":"2018"},"recId":"328318353","disp":"Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapyAmerican journal of transplantation","title":[{"title_sort":"American journal of transplantation","subtitle":"official journal of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST)","title":"American journal of transplantation"}],"note":["Gesehen am 16.06.25"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2001 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"]}]} | ||
| SRT | |a SOMMERERCLFIVEYEAROU0220 | ||